JP2017501205A5 - - Google Patents

Download PDF

Info

Publication number
JP2017501205A5
JP2017501205A5 JP2016544593A JP2016544593A JP2017501205A5 JP 2017501205 A5 JP2017501205 A5 JP 2017501205A5 JP 2016544593 A JP2016544593 A JP 2016544593A JP 2016544593 A JP2016544593 A JP 2016544593A JP 2017501205 A5 JP2017501205 A5 JP 2017501205A5
Authority
JP
Japan
Prior art keywords
alkyl
halo
alkoxy
carbocyclyl
alkanoyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016544593A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017501205A (ja
JP6759100B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/072851 external-priority patent/WO2015103317A1/en
Publication of JP2017501205A publication Critical patent/JP2017501205A/ja
Publication of JP2017501205A5 publication Critical patent/JP2017501205A5/ja
Application granted granted Critical
Publication of JP6759100B2 publication Critical patent/JP6759100B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016544593A 2013-12-30 2014-12-30 治療用阻害化合物 Expired - Fee Related JP6759100B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361921995P 2013-12-30 2013-12-30
US61/921,995 2013-12-30
US201462025203P 2014-07-16 2014-07-16
US62/025,203 2014-07-16
PCT/US2014/072851 WO2015103317A1 (en) 2013-12-30 2014-12-30 Therapeutic inhibitory compounds

Publications (3)

Publication Number Publication Date
JP2017501205A JP2017501205A (ja) 2017-01-12
JP2017501205A5 true JP2017501205A5 (enExample) 2018-02-08
JP6759100B2 JP6759100B2 (ja) 2020-09-23

Family

ID=53493998

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016544593A Expired - Fee Related JP6759100B2 (ja) 2013-12-30 2014-12-30 治療用阻害化合物

Country Status (11)

Country Link
US (2) US10266515B2 (enExample)
EP (1) EP3089746A4 (enExample)
JP (1) JP6759100B2 (enExample)
KR (1) KR20160106627A (enExample)
CN (1) CN106061480B (enExample)
AU (2) AU2014373735B2 (enExample)
BR (1) BR112016015449A8 (enExample)
CA (1) CA2935683A1 (enExample)
EA (1) EA032713B1 (enExample)
MX (1) MX2016008688A (enExample)
WO (1) WO2015103317A1 (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
MX342288B (es) 2010-04-22 2016-09-23 Vertex Pharma Proceso para producir compuestos de cicloalquilcarboxamido-indol.
TWI636047B (zh) 2013-08-14 2018-09-21 英商卡爾維斯塔製藥有限公司 雜環衍生物
HUE14755117T2 (hu) 2013-08-14 2018-12-28 Kalvista Pharmaceuticals Ltd Plazma-kallikrein inhibitorok
US9611252B2 (en) 2013-12-30 2017-04-04 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
KR20160106627A (ko) 2013-12-30 2016-09-12 라이프에스씨아이 파마슈티컬스, 인크. 치료적 억제 화합물
KR102447581B1 (ko) 2014-04-15 2022-09-28 버텍스 파마슈티칼스 인코포레이티드 낭포성 섬유증 막전도 조절자 매개 질환 치료용 약제학적 조성물
EA035410B1 (ru) * 2014-07-16 2020-06-09 Лайфсай Фармасьютикалс, Инк. Терапевтические соединения-ингибиторы
GB201421085D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
US12282014B2 (en) 2015-11-19 2025-04-22 Dana-Farber Cancer Institute, Inc. Methods of identifying compounds that interfere with ERG-driven misguidance of BAF complexes in TMPRSS2-ERG driven prostate cancers
EP3404021A4 (en) 2016-01-12 2019-09-11 Nippon Chemiphar Co., Ltd. VOLTAGE-RELATED T-TYPE CALCIUM CHANNEL INHIBITOR
SG10201913616UA (en) 2016-05-31 2020-03-30 Kalvista Pharmaceuticals Ltd Pyrazole derivatives as plasma kallikrein inhibitors
GB201609603D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
EP3481391A4 (en) 2016-07-11 2020-03-11 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
CN107033015B (zh) * 2017-06-02 2019-04-30 南京欧信医药技术有限公司 一种药物中间体的合成方法
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
MX2020005168A (es) 2017-11-29 2020-08-20 Kalvista Pharmaceuticals Ltd Formas de dosificacion que contienen un inhibidor calicreina de plasma.
EP3746124A4 (en) 2018-01-30 2021-10-27 Foghorn Therapeutics Inc. COMPOUNDS AND THEIR USES
WO2019166874A1 (en) * 2018-02-28 2019-09-06 Lifesci Pharmaceuticals, Inc. Treatment of hereditary angioedema
IL277071B2 (en) 2018-03-08 2024-07-01 Incyte Corp AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS
WO2019178129A1 (en) 2018-03-13 2019-09-19 Shire Human Genetic Therapies, Inc. Substituted imidazopyridines as inhibitors of plasma kallikrein and uses thereof
KR20210016545A (ko) 2018-05-29 2021-02-16 오메로스 코포레이션 Masp-2 억제제 및 사용 방법
US11584714B2 (en) 2018-05-29 2023-02-21 Omeros Corporation MASP-2 inhibitors and methods of use
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
WO2020081588A1 (en) 2018-10-17 2020-04-23 Dana-Farber Cancer Institute, Inc. Swi/snf family chromatin remodeling complexes and uses thereof
US12384776B2 (en) 2019-01-29 2025-08-12 Foghorn Therapeutics Inc. Compounds and uses thereof
CN110256342B (zh) * 2019-07-16 2022-06-07 河南省科学院化学研究所有限公司 一种2-氰基喹啉衍生物的合成方法
WO2021028645A1 (en) 2019-08-09 2021-02-18 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors
PT4031547T (pt) 2019-09-18 2024-08-27 Takeda Pharmaceuticals Co Inibidores de calicreína plasmática e utilizações dos mesmos
WO2021055589A1 (en) 2019-09-18 2021-03-25 Shire Human Genetic Therapies, Inc. Heteroaryl plasma kallikrein inhibitors
CN115103709A (zh) 2019-12-04 2022-09-23 奥默罗斯公司 Masp-2抑制剂和使用方法
IL293588A (en) 2019-12-04 2022-08-01 Omeros Corp 2-masp inhibitor compounds, preparations containing them and their uses
AU2020395306B2 (en) 2019-12-04 2025-04-24 Omeros Corporation MASP-2 inhibitors and methods of use
CR20220316A (es) 2019-12-06 2022-10-07 Vertex Pharma Tetrahidrofuranos sustituidos como moduladores de canales de sodio
JP7561195B2 (ja) 2020-01-29 2024-10-03 フォグホーン セラピューティクス インコーポレイテッド 化合物及びその使用
EP4096668A4 (en) * 2020-01-29 2024-02-28 Foghorn Therapeutics Inc. Compounds and uses thereof
US12383555B2 (en) 2020-05-20 2025-08-12 Foghorn Therapeutics Inc. Methods of treating cancers
JP2024522292A (ja) 2021-06-04 2024-06-13 バーテックス ファーマシューティカルズ インコーポレイテッド ナトリウムチャネルのモジュレーターとしてのn-(ヒドロキシアルキル(ヘテロ)アリール)テトラヒドロフランカルボキサミド
TW202337455A (zh) 2021-12-09 2023-10-01 美商迪賽孚爾製藥有限公司 Raf激酶抑制劑及其使用方法
WO2024059186A1 (en) * 2022-09-15 2024-03-21 Takeda Pharmaceutical Company Limited N-((isoquinolin-6-yl)methyl)-1h-pyrazole-4-carboxamid derivatives as plasma kallikrein inhibitors for the treatment of hereditary angioedema
CN119604497A (zh) * 2023-06-30 2025-03-11 远森制药(杭州)有限公司 杂芳族甲酰胺类化合物及其在医药上的应用
WO2025160190A1 (en) * 2024-01-23 2025-07-31 Retune Pharma Inc. Therapeutic inhibitory compounds

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW212792B (enExample) * 1991-09-13 1993-09-11 Shell Internat Res Schappej B V
IL108459A0 (en) * 1993-02-05 1994-04-12 Opjohn Company 4-Hydroxy-benzopyran-2-ones and 4-hydroxy-cycloalkyl [B] pyran-2-ones useful for treating infections due to hiv and other retroviruses
AU707748B2 (en) 1994-03-25 1999-07-22 Isotechnika Inc. Enhancement of the efficacy of drugs by deuteration
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
TW575562B (en) * 1998-02-19 2004-02-11 Agrevo Uk Ltd Fungicides
DK1228067T3 (da) * 1999-11-10 2004-12-06 Takeda Chemical Industries Ltd 5-leddede heterocykliske forbindelser med hypoglykæmisk og hypolipidæmisk virkning
EA007987B1 (ru) * 2002-03-29 2007-02-27 Чирон Корпорейшн Замещённые бензазолы и их применение в качестве ингибиторов киназы raf
EP1603884A4 (en) * 2003-02-28 2008-05-28 Encysive Pharmaceuticals Inc PYRIDINE, PYRIMIDINE, QUINOLINE, QUINAZOLINE AND NAPHTHALENE UROTENSIN II RECEPTOR ANTAGONISTS
GB0403155D0 (en) * 2004-02-12 2004-03-17 Vernalis Res Ltd Chemical compounds
KR20070066988A (ko) * 2005-12-22 2007-06-27 크리스탈지노믹스(주) 단백질 키나아제 활성을 저해하는 아미노 피리미딘유도체와 이의 제조방법 및 이를 유효성분으로 함유하는약학 조성물
US20070254894A1 (en) * 2006-01-10 2007-11-01 Kane John L Jr Novel small molecules with selective cytotoxicity against human microvascular endothelial cell proliferation
JP2009528992A (ja) 2006-02-16 2009-08-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 可溶性エポキシド加水分解酵素阻害剤として有益な置換ピリジンアミン化合物
CL2007003609A1 (es) * 2006-12-14 2008-07-25 Bayer Schering Pharma Ag Compuestos derivados de dihidropiridinas sustituidas; proceso de preparacion; compuestos intermediarios; composicion farmaceutica; proceso para producir la composicion farmaceutica; y uso en el tratamiento de una enfermedad mejorada con la inhibicion
EP2129670A2 (en) * 2007-02-16 2009-12-09 Glaxo Group Limited Benzofuran compounds useful in the treatment of conditions mediated by the action of pge2 at the ep1 receptor
EP2002834A1 (de) * 2007-06-13 2008-12-17 Bayer Schering Pharma Aktiengesellschaft Aryl/Hetarylamide als Modulatoren des EP2-Rezeptors
WO2009083553A1 (en) * 2007-12-31 2009-07-09 Rheoscience A/S Azine compounds as glucokinase activators
EP2269990A4 (en) * 2008-03-25 2012-04-18 Takeda Pharmaceutical Heterocyclic compound
US20090270407A1 (en) 2008-04-25 2009-10-29 E. I. Du Pont De Nemours And Company Fungicidal isoxazolidines
CN102099339A (zh) 2008-07-18 2011-06-15 武田药品工业株式会社 苯并氮杂衍生物及其作为组胺h3拮抗剂的用途
US8598209B2 (en) 2008-10-31 2013-12-03 Merck Sharp & Dohme Corp. P2X3, receptor antagonists for treatment of pain
WO2010108733A1 (en) * 2009-03-26 2010-09-30 Syngenta Participations Ag Insecticidal compounds
GB201004739D0 (en) * 2010-03-22 2010-05-05 Prosidion Ltd Receptor modulators
US9290485B2 (en) * 2010-08-04 2016-03-22 Novartis Ag N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides
MX366318B (es) * 2010-11-19 2019-07-05 Ligand Pharm Inc Derivados de aminas heterocíclicas que inhiben la transducción de señal mediana por cinasa asociada con el receptor de interleucina-1.
GB201021103D0 (en) * 2010-12-13 2011-01-26 Univ Leuven Kath New compounds for the treatment of neurodegenerative diseases
US9321727B2 (en) * 2011-06-10 2016-04-26 Hoffmann-La Roche Inc. Pyridine derivatives as agonists of the CB2 receptor
CN102904742B (zh) 2011-07-29 2015-10-07 华为终端有限公司 对可执行节点的操作方法及系统
WO2013040436A2 (en) 2011-09-16 2013-03-21 The Regents Of The University Of Michgian Esx-mediated transcription modulators and related methods
US9206128B2 (en) * 2011-11-18 2015-12-08 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
EP2807157A1 (en) * 2012-01-27 2014-12-03 Novartis AG 5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
EP2807156A1 (en) 2012-01-27 2014-12-03 Novartis AG Aminopyridine derivatives as plasma kallikrein inhibitors
EA027780B1 (ru) 2012-12-07 2017-08-31 Ф.Хоффманн-Ля Рош Аг Пиридин-2-амиды, пригодные в качестве агонистов каннабиноидного рецептора 2
RU2712621C2 (ru) 2013-05-23 2020-01-30 Калвиста Фармасьютикалз Лимитед Азотсодержащие гетероциклические производные, полезные в качестве ингибитора калликреина плазмы
HUE14755117T2 (hu) 2013-08-14 2018-12-28 Kalvista Pharmaceuticals Ltd Plazma-kallikrein inhibitorok
US9611252B2 (en) 2013-12-30 2017-04-04 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
KR20160106627A (ko) 2013-12-30 2016-09-12 라이프에스씨아이 파마슈티컬스, 인크. 치료적 억제 화합물
EA035410B1 (ru) 2014-07-16 2020-06-09 Лайфсай Фармасьютикалс, Инк. Терапевтические соединения-ингибиторы
GB201421088D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
EP3481391A4 (en) 2016-07-11 2020-03-11 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds

Similar Documents

Publication Publication Date Title
JP2017501205A5 (enExample)
PH12019500830A1 (en) 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer
CY1120342T1 (el) Ανταγωνιστης πολυκυκλικου lpa1 και χρησεις εξ' αυτου
MX377635B (es) Inhibidores de 3-haloalilamina sustituidos de ssao y uso de los mismos
CY1120248T1 (el) Ενωσεις ιμιδαζο[4,5-c]κινολιν-2-ονης και η χρηση τους στη θεραπευτικη αντιμετωπιση του καρκινου
JP2016513137A5 (enExample)
JP2016530283A5 (enExample)
AR087545A1 (es) 1h-imidazo[4,5-c]quinolina sustituidos con actividad inhibitoria de bromodominio
JP2013510124A5 (enExample)
IN2014MN02106A (enExample)
CY1118721T1 (el) Παραγωγα 2,3 διϋδρο-1η-ινδεν-1-υλ-2,7-διαζασπειρο[3.6]εννεανιου και η χρηση αυτων ως ανταγωνιστες ή αντιστροφοι αγωνιστες του υποδοχεα γκρελινης
CL2013002690A1 (es) Compuestos derivados de bis(fluoroalquil)-1,4-benzodiazepinona, inhibidores de notch; compuesto cristalino; composicion farmaceutica que los comprende; combinacion farmaceutica; y su uso para el tratamiento del cancer.
EA201592256A1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
EA201070929A1 (ru) ФУРО- И ТИЕНО[3,2-c]ПИРИДИНЫ
HRP20211278T1 (hr) Supstituirani derivati indolina kao inhibitori replikacije denga virusa
HRP20181048T1 (hr) Neuroaktivni 19-alkoksi-17-supstituirani steroidi, korisni u postupcima liječenja
UA104489C2 (uk) Сполуки для лікування дисліпідемії та споріднених хвороб
HRP20171648T1 (hr) Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze
RU2013144571A (ru) Алинзамещенные хиназолины и способы их применения
EA201400067A1 (ru) Новая терапевтическая композиция, содержащая апоморфин в качестве активного ингредиента
CR20160527A (es) Derivados de carboxamida
EA201691058A1 (ru) Производные пирролопирролона и их применение для лечения заболеваний
WO2012135615A3 (en) Enopeptins, uses thereof, and methods of synthesis thereto
WO2016127168A3 (en) Mebendazole polymorph for treatment and prevention of tumors
UY36123A (es) Derivados de carboxamida